WEBINAR - TCR-T as an T-cell immunotherapy option for malignant hematology patients

WEBINAR - TCR-T as an T-cell immunotherapy option for malignant hematology patients
Evenemanget har utgått

New advances in clinical research has found that stimulating the natural defenses of a person’s immune system to kill cancer cells, known as immunotherapy, has become a novel and exciting approach to treat cancer with many positive outcomes for certain indications. CAR T-cell Therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumor development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR-T) has also shown great potential.

Join our free webinar and listen to Kai Pinkernell MD Chief Medical Officer, Chief Development Officer, Medigene AG and Peter van Balen MD, Internist-hematologist, Head of the Laboratory for Specialized Hematology, Leiden University Medical Center who will be talking about the industry and their expertise on the “Development of a TCR modified T-cell Immunotherapy in hematologic malignancies.

 

Dela

Information

När: ons, 27 jan 2021 15:00 till 16:00
Var: Live Webinar
Arrangör: TFS International AB
Språk: Engelska

Anmälan

Länk till webbplats eller e-postadress
Sista anmälningsdag

Kategori

Seminarium/utbildning

Kontaktinformation

Gordana Claveres
0708540051
gordana.claveres@tfscro.com
www.tfscro.com